Calix (CALX) CEO sells 274,000 shares under Rule 10b5-1

Calix (CALX) reported insider transactions by President & CEO Michael Weening.

Rhea-AI Filing Summary

Calix (CALX) reported insider transactions by President & CEO Michael Weening. He exercised 274,000 stock options at $7.84 and sold 274,000 shares pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

On 10/30/2025, he exercised 200,000 shares, then sold 150,000 shares at a weighted average $64.628 (range $64.55–$65.00) and 50,000 shares at $67.5456 (range $67.35–$67.93). On 11/03/2025, he exercised 74,000 shares and sold 74,000 shares at $67.4203 (range $66.245–$69.450). Shares beneficially owned were 16,117 after the reported transactions. The options exercised were fully vested as of November 27, 2023 and expire on November 27, 2029.

Insider Trade Summary

Exercise and Sale: 274,000 shares ($15.91M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Weening Michael

Role President & CEO

Sold 274,000 shs ($18.06M)

Approx. gross sale proceeds $18.06M

Approx. exercise cost $2.15M

Approx. pre-tax spread $15.91M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	74,000	$0.00	$0.00
Exercise	Common Stock	74,000	$7.84	$580K
Sale	Common Stock	74,000	$67.4203	$4.99M
Exercise	Stock Option (right to buy)	200,000	$0.00	$0.00
Exercise	Common Stock	200,000	$7.84	$1.57M
Sale	Common Stock	150,000	$64.628	$9.69M
Sale	Common Stock	50,000	$67.5456	$3.38M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 16,117 shares (Direct)

Footnotes (4)

1. F1. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $64.55 to $65.00, inclusive. Full information on the number of shares sold at each sale price is available upon request.
2. F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.35 to $67.93, inclusive. Full information on the number of shares sold at each sale price is available upon request.
3. F3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.245 to $69.450, inclusive. Full information on the number of shares sold at each sale price is available upon request.
4. F4. 100% of the shares subject to the option were fully vested and exercisable on November 27, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Calix (CALX) disclose?

CEO Michael Weening exercised 274,000 options at $7.84 and sold 274,000 shares under a Rule 10b5-1 plan.

What were the sale prices reported in the Calix (CALX) Form 4?

Weighted averages: $64.628 (range $64.55–$65.00), $67.5456 (range $67.35–$67.93), and $67.4203 (range $66.245–$69.450).

How many Calix (CALX) shares does the CEO hold after these trades?

The Form 4 reports 16,117 shares beneficially owned following the transactions.

Were the Calix (CALX) CEO’s sales under a trading plan?

Yes. Sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

What options did the Calix (CALX) CEO exercise?

Stock options with a $7.84 exercise price, fully vested as of November 27, 2023, expiring on November 27, 2029.

On which dates did the Calix (CALX) transactions occur?

Reported dates: October 30, 2025 and November 3, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 07:11 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weening Michael

(Last) (First) (Middle)

C/O CALIX, INC.

3155 OLSEN DRIVE, SUITE 450

(Street)

SAN JOSE CA 95117

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CALIX, INC [ (CALX) ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		M		200,000	A	$7.84	216,117	D
Common Stock	10/30/2025		S		150,000	D	$64.628(1)	66,117	D
Common Stock	10/30/2025		S		50,000	D	$67.5456(2)	16,117	D
Common Stock	11/03/2025		M		74,000	A	$7.84	90,117	D
Common Stock	11/03/2025		S		74,000	D	$67.4203(3)	16,117	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.84	10/30/2025		M			200,000	(4)	11/27/2029	Common Stock	200,000	$0	74,000	D
Stock Option (right to buy)	$7.84	11/03/2025		M			74,000	(4)	11/27/2029	Common Stock	74,000	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $64.55 to $65.00, inclusive. Full information on the number of shares sold at each sale price is available upon request.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.35 to $67.93, inclusive. Full information on the number of shares sold at each sale price is available upon request.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.245 to $69.450, inclusive. Full information on the number of shares sold at each sale price is available upon request.

4. 100% of the shares subject to the option were fully vested and exercisable on November 27, 2023.

Remarks:

Sales reported on the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

	/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.